Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 ...
RARITAN, N.J., July 21 Ortho Clinical Diagnostics today announced the U.S. Food and Drug Administration (FDA) approval of the VITROS((R)) Anti-HCV assay for use on the VITROS 5600((R)) Integrated and ...
RARITAN, New Jersey, June 11, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, ...
Raritan-based Ortho Clinical Diagnostics said April 3, it is launching to market its COVID-19 antibody test. The VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack testing kits are ...
RARITAN, N.J. -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac ...
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, has submitted a premarket approval (PMA) application to the US Food and Drug Administration (FDA) for the Vitros ...
- Ortho's VITROS® SARS-CoV-2 Antigen Test is the first high-volume COVID-19 antigen test to receive Food and Drug Administration (FDA) Emergency Use Authorization (EUA). - With utility for mass-scale ...
- RARITAN, New Jersey, April 16, 2019 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced CE Mark for its next-generation VITROS® High Sensitivity Troponin I ...
RARITAN, NJ--(Marketwired - Jun 6, 2017) - Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced the launch of its VITROS® NephroCheck® test, the first fully automated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback